Medical News Hubb
Advertisement
  • Home
  • News
  • Pharmaceutical
  • Medicines & Healthy Lifestyle
  • Contact us
No Result
View All Result
  • Home
  • News
  • Pharmaceutical
  • Medicines & Healthy Lifestyle
  • Contact us
No Result
View All Result
Medical News Hubb
No Result
View All Result
Home Pharmaceutical

Medical Bulletin 12/September/2022

admin by admin
September 12, 2022
in Pharmaceutical



Here are the top medical news for the day:

Study finds antibiotics may worsen melanoma: Here’s how
The use of broad-spectrum antibiotics in mice with malignant melanoma, an aggressive form of skin cancer, accelerated their metastatic bone growth, likely because the drugs depleted the mice’s intestinal flora and weakened their immune response, according to a new study by researchers at Emory University in Atlanta.
The researchers hypothesized that using antibiotics to deplete the gut microbiome of mice would affect their intestinal immune cells and thus alter their immune response, leading to accelerated bone metastasis. They injected B16‐F10 melanoma cells into the hearts and bones of mice that had been treated with broad‐spectrum antibiotics. As predicted, the antibiotic injections accelerated bone metastatic growth in those mice, compared with control mice that had not received the shots.
Ref:
MEETING ASBMR 2022 Annual Meeting
Air pollution may trigger lung cancer in never-smokers
A new mechanism has been identified through which very small pollutant particles in the air may trigger lung cancer in people who have never smoked, paving the way to new prevention approaches and development of therapies, according to late-breaking data [to be] reported at the ESMO Congress 2022.
In the laboratory studies, the Francis Crick Institute scientists showed that the same pollutant particles (PM2.5) promoted rapid changes in airway cells which had mutations in EGFR and in another gene linked to lung cancer called KRAS, driving them towards a cancer stem cell like state.
Ref:
Charles Swanton et al,Annals of Oncology
Progression-free survival in advanced melanoma improved by Cell therapy
A novel treatment strategy with personalized cell therapy significantly improves progression-free survival compared to standard immunotherapy in patients with advanced melanoma, according to ground-breaking results reported at the ESMO Congress 2022 from the phase 3 M14TIL trial.
The treatment essentially involves taking a small sample from a patient’s resected tumor, growing immune T cells from the tumor in the laboratory and then infusing the personalized TIL therapy back into the patient following chemotherapy. TILs recognize tumor cells as abnormal, penetrate them and then work to kill them.
JOURNAL Annals of Oncology, MEETING ESMO Congress 2022



Source link

Tags: air pollutionAnnals of Oncologyantibioticsbonecancercancer patientsdrugsheartimmune cellsimmunotherapylung cancermalignant melanomamelanomamiceoncologyskin cancersolid tumorstissue samples
Previous Post

Telehealth Widely Popular Among Health Care Providers, Survey Finds

Next Post

Liver Cancer Exacts High Financial Toll on Older Adults

Next Post

Liver Cancer Exacts High Financial Toll on Older Adults

Recommended

Another Lie: ‘Information Disorder’ and How to Resist

December 20, 2022

Triple-negative breast cancer reflects health inequities in the U.S.

August 8, 2022

Don't miss it

Pharmaceutical

ALS Association battles its chapters over money, priorities

February 3, 2023
Medicines & Healthy Lifestyle

Surgery and Prescriptions Now Advised for Obese Children?

February 3, 2023
Medicines & Healthy Lifestyle

Jesduvroq Approved for Anemia of CKD in Patients on Dialysis

February 3, 2023
Medicines & Healthy Lifestyle

Prescribing Medication Dosage According To DNA Profile Lowers Side Effects By 30%: Study

February 3, 2023
News

Longer Diabetes Duration Links With Increased Heart Failure

February 3, 2023
Pharmaceutical

Health Bulletin 3/ February/ 2023

February 3, 2023

© 2022 Medical News Hubb All rights reserved.

Use of these names, logos, and brands does not imply endorsement unless specified. By using this site, you agree to the Privacy Policy and Terms & Conditions.

Navigate Site

  • Home
  • News
  • Pharmaceutical
  • Medicines & Healthy Lifestyle
  • Contact us

Newsletter Sign Up

No Result
View All Result
  • Home
  • News
  • Pharmaceutical
  • Medicines & Healthy Lifestyle
  • Contact us

© 2022 Medical News Hubb All rights reserved.